ArticlePathogens (Basel, Switzerland)2020
Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo.
Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Doxycycline for the treatment of nodding syndrome: a randomised, placebo-controlled, phase 2 trial.The Lancet. Global health · 2024Trial
- Declining Onchocerca volvulus transmission despite limited ivermectin delivery in the Kakoi-Koda focus, Ituri, Democratic Republic of the Congo: An epidemiological, entomological and landscape evidence synthesis.PLoS neglected tropical diseases · 2026Article
- Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021-2023: results of screening for clinical trials of moxidectin versus ivermectin.Parasites & vectors · 2026Article
- Ivermectin exposition during neurulation induces neural tube defects and neuromuscular alterations inFrontiers in pharmacology · 2026Article
- Community-directed treatment with ivermectin in Maridi, South Sudan: Impact of an onchocerciasis awareness campaign and bi-annual treatment on therapeutic coverage.PLoS neglected tropical diseases · 2025Article
- New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development.CNS drugs · 2023Review
- Epilepsy and nodding syndrome in association with an Onchocerca volvulus infection drive distinct immune profile patterns.PLoS neglected tropical diseases · 2023Article
- AssessingPathogens (Basel, Switzerland) · 2023Article
- Article
- Onchocerciasis drug development: from preclinical models to humans.Parasitology research · 2021Review
- Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis.Life (Basel, Switzerland) · 2021Article
- No Evidence for the Involvement of Leiomodin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy.Pathogens (Basel, Switzerland) · 2021Article
- Serotonin Levels in the Serum of Persons with Onchocerciasis-Associated Epilepsy: A Case-Control Study.Pathogens (Basel, Switzerland) · 2021Article
- Potential Parasitic Causes of Epilepsy in an Onchocerciasis Endemic Area in the Ituri Province, Democratic Republic of Congo.Pathogens (Basel, Switzerland) · 2021Article
- Community perceptions and attitudes regarding epilepsy and disease cost after implementation of a community-based epilepsy treatment program in onchocerciasis-endemic communities in the Democratic Republic of Congo.Epilepsy & behavior : E&B · 2021Article
- Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation.PLoS neglected tropical diseases · 2021Review
- Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected withPathogens (Basel, Switzerland) · 2020Article
- Ivermectin Treatment Response in Onchocerca Volvulus Infected Persons with Epilepsy: A Three-Country Short Cohort Study.Pathogens (Basel, Switzerland) · 2020Article
- Comparison of Diagnostic Tests forPathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundThere is anecdotal evidence that ivermectin may decrease seizure frequency in
methodsIn October 2017, a 12-month clinical trial was initiated in rural Democratic Republic of Congo. PWE with onchocerciasis-associated epilepsy experiencing ≥2 seizures/month were randomly allocated to receive, over a one-year period, ivermectin once or thrice (group 1), while other onchocerciasis-infected PWE (OIPWE) were randomized to ivermectin twice or thrice (group 2). All participants also received anti-epileptic drugs. Data was analyzed using multiple logistic regression.
resultsWe enrolled 197 participants. In an intent-to-treat analysis (data from group 1 and 2 combined), seizure freedom was more likely among OIPWE treated with ivermectin thrice (OR: 5.087, 95% CI: 1.378-19.749;
conclusionsIncreasing the number of ivermectin treatments was found to suppress both microfilarial density and seizure frequency in OIPWE, suggesting that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.